Ecolectro | $10,500,000 | (Nov 15, 2024)
Workflow | $3,000,000 | (Nov 15, 2024)
runQL | $1,600,000 | (Nov 15, 2024)
Certified by Founder
Lodge
Quell Therapeutics
start up
United Kingdom
- London, London
- 29/11/2021
- Series B
- $156,000,000
An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions.
Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.
- Industry Biotechnology Research
- Website https://quell-tx.com/
- LinkedIn https://www.linkedin.com/company/quell-therapeutics/about/
ELICIT PLANT | $48,000,000 | (Nov 15, 2024)
Sunthetics | $4,000,000 | (Nov 15, 2024)
Vaulted Deep | $32,300,000 | (Nov 15, 2024)
Serenity | $5,500,000 | (Nov 15, 2024)
Airbound | $1,700,000 | (Nov 15, 2024)
Influur | $10,000,000 | (Nov 15, 2024)
Naturbeads | $9,890,632 | (Nov 15, 2024)
TestSprite | $1,500,000 | (Nov 15, 2024)
Impilo | $11,500,000 | (Nov 15, 2024)